The outcomes on the SURPASS trials reveal that tirzepatide yields clinically significant advancements in glycemic Regulate and fat reduction in comparison with other GLP-one receptor agonists (semaglutide and dulaglutide), insulin degludec, and insulin glargine.are breastfeeding or decide to breastfeed. Breastfeeding will not be recommended during